english.prescrire.org > Spotlight > Archives : 2022 > Fostemsavir (Rukobia°) in multidrug-resistant HIV-1 infection

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2022 : 1 | 30 | 60

Fostemsavir (Rukobia°) in multidrug-resistant HIV-1 infection

The initial treatment for patients with HIV-1 infection is based on a combination of antiretroviral drugs. Sometimes the virus is or becomes resistant to the various drug combinations that are available. How do Prescrire's editors rate fostemsavir (Rukobia°) in this situation?

Prescrire's rating

  •  POSSIBLY HELPFUL  According to the scarce data available as of late 2021, when
    an HIV-1- infected patient has run out of treatment options, adding fostemsavir to "optimised" antiretroviral therapy seems to result in greater antiviral activity. The addition of fostemsavir probably contributed to the undetectable viral load... 


Full review available for download by subscribers, below

©Prescrire 1 May 2022

Source: "Fostemsavir (Rukobia°) in multidrug-resistant HIV-1 infection" Prescrire International 2022; 31 (237): 120-121. Subscribers only.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


Prescrire's rating:
 
Prescrire's rating  
  POSSIBLY HELPFUL 
 
 
See also:

Ibalizumab - Trogarzo°.
In multidrug-resistant
HIV infection: a possible
option when no optimised
antiretroviral regimens
are effective
Prescrire Int 2020;
29 (219): 229-232.
Pdf, subscribers only

"Prescrire's ratings for new
drugs and new indications"
(February 2022)
Free

Read more:

All the subjects in
Prescrire's Spotlight
Free >